Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026
Same author

Influence of Digital Literacy on Digital Health Usage Intention Among Patients With Cancer and Healthcare Providers.

Journal of Korean medical science·2026
Same author

Risk factors for second primary cancer in patients who survive breast cancer.

NPJ breast cancer·2026
Same author

Development of K-CORE: a web-based platform for integrated clinico-genomic analysis.

Life science alliance·2026
Same author

Imaging of Small Cell Lung Cancer: An Updated Overview of Current and Emerging Applications.

Radiology. Imaging cancer·2026
Same author

Delineation of the heterogeneity underlying genomic instability in hereditary breast cancers reveals four disease subtypes.

Experimental & molecular medicine·2026

Related Experiment Video

Updated: Jun 29, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

687

Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for

Chung Ryul Oh1,2, Eo Jin Kim1, Heejung Chae1

  • 1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.

Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|March 31, 2024
PubMed
Summary

Mismatch repair (MMR) status did not impact the effectiveness of first-line fluoropyrimidine plus platinum chemotherapy in patients with advanced gastric cancer. These findings suggest MMR status is not a predictive biomarker for this treatment in mGC.

Keywords:
ChemotherapyEfficacyMetastatic gastric cancerMismatch repair deficiency

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

5.5K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

261

Related Experiment Videos

Last Updated: Jun 29, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

687
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

5.5K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

261

Area of Science:

  • Oncology
  • Gastrointestinal Cancer Research
  • Cancer Biomarkers

Background:

  • Gastric cancer (GC) remains a significant global health challenge, particularly in its metastatic, recurrent, or unresectable (mGC) forms.
  • First-line chemotherapy regimens, including fluoropyrimidine plus platinum (FP), are standard treatments for mGC.
  • The role of mismatch repair (MMR) status as a predictive biomarker for chemotherapy efficacy in mGC requires further elucidation.

Purpose of the Study:

  • To investigate the impact of mismatch repair (MMR) status on the efficacy of first-line fluoropyrimidine plus platinum (FP) chemotherapy in patients with HER2-negative metastatic, recurrent, or unresectable gastric cancer (mGC).
  • To determine if MMR deficiency (dMMR) influences treatment outcomes compared to proficient MMR (pMMR) status.

Main Methods:

  • Retrospective review of 543 patients with mGC who received first-line FP chemotherapy between 2015 and 2018.
  • Evaluation of clinical characteristics and chemotherapy efficacy based on MMR protein expression status (dMMR vs. pMMR) using immunohistochemistry.
  • Analysis of objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Main Results:

  • Of 543 analyzed patients, 4.4% had deficient MMR (dMMR).
  • Patients with dMMR were older and less likely to have signet ring cell carcinoma (SRCC) compared to pMMR patients.
  • No significant differences in ORR (27.3% vs. 34.3%), PFS (median 5.6 vs. 5.8 months), or OS (median 17.9 vs. 12.2 months) were observed between dMMR and pMMR groups.

Conclusions:

  • First-line FP chemotherapy efficacy is not significantly different between patients with dMMR and pMMR gastric cancer.
  • MMR status does not appear to be a predictive biomarker for response to first-line FP chemotherapy in mGC.
  • Further research may be warranted to explore other biomarkers or treatment strategies for dMMR mGC.